Market Cap 468.13B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 24.38
Forward PE 18.85
Profit Margin 6.91%
Debt to Equity Ratio -12.03
Volume 1,363,868
Avg Vol 6,974,502
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 94%
Beta 0.30
Analysts Strong Sell
Price Target $276.37

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
TwongStocks
TwongStocks Aug. 26 at 5:21 PM
$APGE Equity Corporate Actions Alert #2026 - 607 Information Regarding the Merger of Apogee Therapeutics, Inc. (APGE) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-607 At a special meeting held on August 11, 2026, the shareholders of Apogee Therapeutics, Inc. (APGE), approved the proposed merger with and into AbbVie Inc. (NYSE: $ABBV ). The merger is tentatively scheduled to close prior to the market open on September 3, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on September 2, 2026. If the merger closes as anticipated, the stock will remain halted on the day of closing (September 3rd) and will be suspended effective September 4, 2026. APGE shareholders will receive $135.11 per share at closing.
0 · Reply
Primeoptionsst
Primeoptionsst Aug. 26 at 5:08 PM
🚨 $ABBV UPDATE 🚨 ABBV is pulling back after getting rejected around the $266 area. But here’s the important part: the company’s fundamentals remain strong. 📊 Q2 revenue: $16.99B (+10.2% YoY) 💰 Adjusted EPS: $3.65 🔥 Skyrizi: +24% 🔥 Rinvoq: +24% ⚠️ Humira: -35.9% AbbVie also raised its 2026 revenue outlook to roughly $67.6B, while slightly lowering EPS guidance because of the Apogee acquisition. For the chart, I’m watching $266$267.47 as the key upside zone. If ABBV reclaims that area with volume, momentum could strengthen. If it keeps losing support instead, I want to see stabilization before calling a reversal. Strong company ≠ automatic bullish trade. Let price confirm. 📈
0 · Reply
Pas_wayne
Pas_wayne Aug. 26 at 4:56 PM
$ABBV 28/8 $257.5p @ $1.04 Four-day inside bar + high-confidence downside setup.
0 · Reply
Primeoptionsst
Primeoptionsst Aug. 26 at 4:54 PM
$ABBV 28 AUG 26 $257.5 PUT $1.04
0 · Reply
Snipertradesexpert
Snipertradesexpert Aug. 26 at 4:54 PM
$ABBV 28 AUG 26 $257.5 PUT $1.04
0 · Reply
Alphatrades09
Alphatrades09 Aug. 26 at 4:54 PM
$ABBV 257.5P 8/28 @ 1.04 🦅
0 · Reply
ZacksResearch
ZacksResearch Aug. 26 at 4:32 PM
$LLY vs. $ABBV — which stock has the stronger growth story? 🔥 Lilly’s 2026 sales and EPS estimates imply 35.4% and 48.4% year-over-year growth, respectively, while AbbVie’s imply 10.5% and 40.6%. 🚀 Lilly: $27.6B from Mounjaro + Zepbound in the first half of 2026 📈 AbbVie: Skyrizi + Rinvoq expected to exceed $31B in 2026 💡 Lilly’s stronger growth trajectory and expanding obesity opportunity make it the better pick. Latest LLY news here 👉 https://www.zacks.com/stock/quote/LLY?cid=sm-stocktwits-0-quote_overview-oc-39386&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_39386
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 26 at 3:38 PM
$SLS $MRK $MRNA Gps has proven Effective in preventing relapse and extending survival IN EVERY PREVIOUS TRIAL -- Including 2 Phase 2 Trials for AML Remission Maintenance. *Phase 3 Trial Results Imminent. Oral Aza -Onureg is the SOC for AML Patients in First Remission - achieved a MOS of 24.7 Months. $ABBV Conducted the VIALE-M PH3 trial Combining Oral Az w Venetoclax - it FAILED. GPS MOS in this Same First Remission Setting Achieved PH2 MOS >67.6 Months. SOC: 24.7 --- GPs: > 67.6 Again Note the Key Gps Specific Immune Response. Onureg Ph3 and GPS P2 Patients were not Eligible for Transplant. 6.7% of the Onureg CR1 Patients Subsequently rec'd transplant.
0 · Reply
Tom2772
Tom2772 Aug. 26 at 2:57 PM
$REGN $ABBV $RHHBY Interesting LYTENAVA Interview This interview is already about a week old, but it’s still very interesting and worth highlighting. A sponsored, retina-focused interview for the U.S. LYTENAVA rollout, aimed less at investors and more at raising awareness within the medical community — especially among retina specialists — ahead of the U.S. launch. Bob Jahr, CEO of Outlook Therapeutics, discusses the FDA approval, LYTENAVA, and its path into retina practice. Dr. Barry Kuppermann, MD, PhD, moderates the interview. He is a practicing retina specialist, Professor and Chair of Ophthalmology & Visual Sciences, as well as Director of the Gavin Herbert Eye Institute at UC Irvine. This puts LYTENAVA directly in front of the medical audience that matters for the U.S. launch. Interesting.. very interesting.. 👀 https://eyetube.net/podcasts/new-retina-radio/the-story-behind-lytenava-from-fda-approval-to-retina-practice
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 26 at 5:31 AM
$SLS $ABBV Is any day now a long time to wait for a 10X to 20X Return on an Investment? We are at the finish Line -and at 5 year High Share Price Waiting for the IMMINENTLY DUE PH3 Results. • 106 Days Since the 78th Event -- while we await 80th -- in a trial where we have truly miraculous survival - for 49 Second Remission CR2 Patients, who are too frail, for transplant. • 60th EVENT Dec 10, 2024 - IDMC UNBLINDED ACTUAL MOS and IR DATA - share price jumped 60% including an offering that doubled the share count - SLS MCAP tripled that week. • 72nd EVENT Dec 26th 2025 - 12 Events in 12 months - its now been 106 - the Share Price Doubled • 78th EVENT May 11, 2206 - 6 Events in 4.5 Months - its now been 106 - the Share Price CRANKED -- Nearly Tripling ... The IDMC UNBLINDED ACTUAL PHASE 3 MOS and IR DATA from the INTERIM ANALYSIS that told all the AML players... Gps is Golden - just like ALL Prior Gps trials. https://www.cancernetwork.com/view/galinpepimut-s-completes-phase-3-regal-interim-analysis-in-aml
0 · Reply
Latest News on ABBV
AbbVie Earnings Call Transcript: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 26 days ago

AbbVie Earnings Call Transcript: Q2 2026


AbbVie Earnings release: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 26 days ago

AbbVie Earnings release: Q2 2026


AbbVie Quarterly report: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 26 days ago

AbbVie Quarterly report: Q2 2026


AbbVie Reports Second-Quarter 2026 Financial Results

Jul 31, 2026, 7:47 AM EDT - 26 days ago

AbbVie Reports Second-Quarter 2026 Financial Results


JUVÉDERM® Day Returns to U.S. on August 19

Jul 30, 2026, 8:00 AM EDT - 27 days ago

JUVÉDERM® Day Returns to U.S. on August 19


AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Jun 26, 2026, 8:00 AM EDT - 2 months ago

AbbVie to Host Second-Quarter 2026 Earnings Conference Call


AbbVie's $11 Billion Immunology Bet

Jun 24, 2026, 12:51 PM EDT - 2 months ago

AbbVie's $11 Billion Immunology Bet

APGE


AbbVie to Buy Apogee Therapeutics for $10.9 Billion

Jun 22, 2026, 10:15 AM EDT - 2 months ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE


AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Transcript: M&A announcement


AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Slides: M&A announcement


AbbVie Press release: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Press release: M&A announcement


AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

Jun 22, 2026, 7:42 AM EDT - 2 months ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE


AbbVie strikes $10.9 billion deal for Apogee Therapeutics

Jun 22, 2026, 7:04 AM EDT - 2 months ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE


AbbVie Declares Quarterly Dividend

Jun 18, 2026, 4:05 PM EDT - 2 months ago

AbbVie Declares Quarterly Dividend


TwongStocks
TwongStocks Aug. 26 at 5:21 PM
$APGE Equity Corporate Actions Alert #2026 - 607 Information Regarding the Merger of Apogee Therapeutics, Inc. (APGE) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-607 At a special meeting held on August 11, 2026, the shareholders of Apogee Therapeutics, Inc. (APGE), approved the proposed merger with and into AbbVie Inc. (NYSE: $ABBV ). The merger is tentatively scheduled to close prior to the market open on September 3, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on September 2, 2026. If the merger closes as anticipated, the stock will remain halted on the day of closing (September 3rd) and will be suspended effective September 4, 2026. APGE shareholders will receive $135.11 per share at closing.
0 · Reply
Primeoptionsst
Primeoptionsst Aug. 26 at 5:08 PM
🚨 $ABBV UPDATE 🚨 ABBV is pulling back after getting rejected around the $266 area. But here’s the important part: the company’s fundamentals remain strong. 📊 Q2 revenue: $16.99B (+10.2% YoY) 💰 Adjusted EPS: $3.65 🔥 Skyrizi: +24% 🔥 Rinvoq: +24% ⚠️ Humira: -35.9% AbbVie also raised its 2026 revenue outlook to roughly $67.6B, while slightly lowering EPS guidance because of the Apogee acquisition. For the chart, I’m watching $266$267.47 as the key upside zone. If ABBV reclaims that area with volume, momentum could strengthen. If it keeps losing support instead, I want to see stabilization before calling a reversal. Strong company ≠ automatic bullish trade. Let price confirm. 📈
0 · Reply
Pas_wayne
Pas_wayne Aug. 26 at 4:56 PM
$ABBV 28/8 $257.5p @ $1.04 Four-day inside bar + high-confidence downside setup.
0 · Reply
Primeoptionsst
Primeoptionsst Aug. 26 at 4:54 PM
$ABBV 28 AUG 26 $257.5 PUT $1.04
0 · Reply
Snipertradesexpert
Snipertradesexpert Aug. 26 at 4:54 PM
$ABBV 28 AUG 26 $257.5 PUT $1.04
0 · Reply
Alphatrades09
Alphatrades09 Aug. 26 at 4:54 PM
$ABBV 257.5P 8/28 @ 1.04 🦅
0 · Reply
ZacksResearch
ZacksResearch Aug. 26 at 4:32 PM
$LLY vs. $ABBV — which stock has the stronger growth story? 🔥 Lilly’s 2026 sales and EPS estimates imply 35.4% and 48.4% year-over-year growth, respectively, while AbbVie’s imply 10.5% and 40.6%. 🚀 Lilly: $27.6B from Mounjaro + Zepbound in the first half of 2026 📈 AbbVie: Skyrizi + Rinvoq expected to exceed $31B in 2026 💡 Lilly’s stronger growth trajectory and expanding obesity opportunity make it the better pick. Latest LLY news here 👉 https://www.zacks.com/stock/quote/LLY?cid=sm-stocktwits-0-quote_overview-oc-39386&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_39386
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 26 at 3:38 PM
$SLS $MRK $MRNA Gps has proven Effective in preventing relapse and extending survival IN EVERY PREVIOUS TRIAL -- Including 2 Phase 2 Trials for AML Remission Maintenance. *Phase 3 Trial Results Imminent. Oral Aza -Onureg is the SOC for AML Patients in First Remission - achieved a MOS of 24.7 Months. $ABBV Conducted the VIALE-M PH3 trial Combining Oral Az w Venetoclax - it FAILED. GPS MOS in this Same First Remission Setting Achieved PH2 MOS >67.6 Months. SOC: 24.7 --- GPs: > 67.6 Again Note the Key Gps Specific Immune Response. Onureg Ph3 and GPS P2 Patients were not Eligible for Transplant. 6.7% of the Onureg CR1 Patients Subsequently rec'd transplant.
0 · Reply
Tom2772
Tom2772 Aug. 26 at 2:57 PM
$REGN $ABBV $RHHBY Interesting LYTENAVA Interview This interview is already about a week old, but it’s still very interesting and worth highlighting. A sponsored, retina-focused interview for the U.S. LYTENAVA rollout, aimed less at investors and more at raising awareness within the medical community — especially among retina specialists — ahead of the U.S. launch. Bob Jahr, CEO of Outlook Therapeutics, discusses the FDA approval, LYTENAVA, and its path into retina practice. Dr. Barry Kuppermann, MD, PhD, moderates the interview. He is a practicing retina specialist, Professor and Chair of Ophthalmology & Visual Sciences, as well as Director of the Gavin Herbert Eye Institute at UC Irvine. This puts LYTENAVA directly in front of the medical audience that matters for the U.S. launch. Interesting.. very interesting.. 👀 https://eyetube.net/podcasts/new-retina-radio/the-story-behind-lytenava-from-fda-approval-to-retina-practice
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 26 at 5:31 AM
$SLS $ABBV Is any day now a long time to wait for a 10X to 20X Return on an Investment? We are at the finish Line -and at 5 year High Share Price Waiting for the IMMINENTLY DUE PH3 Results. • 106 Days Since the 78th Event -- while we await 80th -- in a trial where we have truly miraculous survival - for 49 Second Remission CR2 Patients, who are too frail, for transplant. • 60th EVENT Dec 10, 2024 - IDMC UNBLINDED ACTUAL MOS and IR DATA - share price jumped 60% including an offering that doubled the share count - SLS MCAP tripled that week. • 72nd EVENT Dec 26th 2025 - 12 Events in 12 months - its now been 106 - the Share Price Doubled • 78th EVENT May 11, 2206 - 6 Events in 4.5 Months - its now been 106 - the Share Price CRANKED -- Nearly Tripling ... The IDMC UNBLINDED ACTUAL PHASE 3 MOS and IR DATA from the INTERIM ANALYSIS that told all the AML players... Gps is Golden - just like ALL Prior Gps trials. https://www.cancernetwork.com/view/galinpepimut-s-completes-phase-3-regal-interim-analysis-in-aml
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 26 at 4:45 AM
$SLS $ABBV Positive P3 result is coming, any day now, and it'll give Gps the fda greenlight to treat 50,000 Aml remission patients each year and generate $20B a year in real revenue. That is worth a f ton more than the current short rigged $2.89B market cap. Is any Day Now a long time to wait for a 10X to 20X Return on an Investment?
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 26 at 2:20 AM
$SLS $MRK SLS is the Next$MRNA P3 Results Imminent The Gps +Keytruda Phase 2 Combination Trial Data - GPS WT1 Targeted Cancer Vaccine - now in nearly Complete Phase 3 Trial for AML Remission Maintenance is the Closest thing there is to the MRNA Keytruda Trial. Gps has proven Effective in preventing Relapse and Extending Survival 2x 4x in all Prior Trials • Including 2 Phase 2's for AML Remission Maintenance, the Phase 3 Trial Setting. 128 Patients Randomized to BAT - Best Available Treatment or Gps Immunotherapy. Aza+VEN is the BAT for Control ARM Patients, and it Recently Failed 3 Phase 3 Trials conducted by $ABBV - Including Failing the VIALE-M P3 for AML First Remission Maintenance and Failing the VIALE-T Post Transplant Maintenance Trial.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 26 at 2:04 AM
$SLS Gps Phase 1/2 Combination Results w Keytruda $MRK - MOS of 18.4 months for End Stage Refractory, Platinum Resistant Ovarian Cancer Patients. • MOS 18.4 Months / Longer than $IMGN Elahere 16.4 month MOS in the same Exact Setting (- except 50% were refractory / 75% in Gps P2). $ABBV Paid $10B to buy Elahere $IMGN - and GPS PH2 trial results are better. ... https://www.fiercepharma.com/pharma/inside-abbvies-10b-immunogen-buyout-and-bidding-war-it-won $SLS is the Next $MRNA ---
2 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 26 at 12:00 AM
$SLS $ABBV $SLS $ABBV $MRNA Is any day now a long time to wait for a 10X to 20X Return on an Investment? We are at the finish Line -and at 5 year High Share Price Waiting for the IMMINENTLY DUE PH3 Results. • 106 Days Since the 78th Event -- while we await 80th -- in a trial where we have truly miraculous survival - for 49 Second Remission CR2 Patients, who are too frail, for transplant. • 60th EVENT Dec 10, 2024 - IDMC UNBLINDED ACTUAL MOS and IR DATA - share price jumped 60% including an offering that doubled the share count - SLS MCAP tripled that week. • 72nd EVENT Dec 26th 2025 - 12 Events in 12 months - its now been 106 - the Share Price Doubled • 78th EVENT May 11, 2206 - 6 Events in 4.5 Months - its now been 106 - the Share Price CRANKED -- Nearly Tripling ... The IDMC UNBLINDED ACTUAL PHASE 3 MOS and IR DATA from the INTERIM ANALYSIS that told all the AML players... Gps is Golden - just like all the Prior trials. https://www.cancernetwork.com/view/galinpepimut-s-completes-phase-3-regal-interim-analysis-in-aml
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 25 at 9:36 PM
$SLS 28 Weeks of Survival w BAT vs 28 Months of Survival for GPs Immune Responders ... in end stage Mesothelioma. -- Immune response is correlated with Extended Survival in all GPs Trials - IDMC UNBLINDED P3 Interim Data: Gps Elicted Immune Response in 80% of Tested Patients.... Gps has proven effective preventing relapse and extending survival in all 7 prior Trials. - Including 2 Phase 2 Trials for AML remission maintenance ... and while we are seeing Miraculous Survival in this Imminently Finished P3... -- Aza+VEN the BAT for Control Arm Patients - Recently FAILED 3 Large Phase 3 Trials Conducted by $ABBV - including Failing 2 P3's for AML Maintenance - VIALE-M and VIALE-T FAILED. - 10 15x Bagger ANY DAY NOW
0 · Reply
Beamen216
Beamen216 Aug. 25 at 7:31 PM
$ABBV its struggling with that 267 mark. Maybe a quick trip to the 250s and we'll try again in a month or so
0 · Reply
DidYouReadThis
DidYouReadThis Aug. 25 at 7:09 PM
Do you think $OTLK #buyers or #sellers are more likely to know which drug in the wet AMD space has had the greatest number of total patients over the last 20 years? #Congrats to #Outlook #Therapeutics on #FDA #Approval! $REGN $ABBV $NVS
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 25 at 6:46 PM
$SLS Gps is worth At LEAST $10B $49.50 per SLS Share Just for Ovarian Cancer Remission Maintenance ala $MRNA adding $40B for Melanoma Remission Maintenance. Gps has proven successful in ALL prior Trials, including 2 for AML Remission Maintenance as well as this Gps Phase 1/2 Combination Results w $MRK Keytruda - MOS of 18.4 months for Endstage Refractory, Platinum Resistant Ovarian Cancer Patients. MOS 18.4 Months / Longer than Elahere 16.4 month MOS in the same Exact Setting - except 50% were refractory / 75% w Gps. $ABBV Paid $10B to buy Elahere $IMGN - and GPS PH2 trial results are better. ... https://www.fiercepharma.com/pharma/inside-abbvies-10b-immunogen-buyout-and-bidding-war-it-won
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 25 at 6:28 PM
$SLS $ABBV We are at the finish Line. • 106 Days Since the 78th Event -- while we await 80 -- in a trial where we are AGAIN - like in ALL Prior GPS Trials - Seeing Truly Miraculous survival - for 49 CR2 - Second Remission Patients, who continue to Survive at Least 30 months, too frail, for Transplant, only a 8 month LE. • 60th EVENT Dec 10, 2024 - IDMC UNBLINDED ACTUAL MOS and IR DATA - share price jumped 60% including an offering that doubled the share count - SLS MCAP tripled that week. • 72nd EVENT Dec 26th 2025 - 12 Events in 12 months - its now been 106 - the Share Price Doubled • 78th EVENT May 11, 2206 - 6 Events in 4.5 Months - its now been 106 - again the Share Price CRANKED -- Nearly Tripling ... The IDMC UNBLINDED ACTUAL PHASE 3 MOS and IR DATA from the INTERIM ANALYSIS that told all the AML players...
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 25 at 6:18 PM
$SLS Of course, Gps Phase 1/2 Combination Results w Keytruda - MOS of 18.4 months for Endstage Refractory, Platinum Resistant Ovarian Cancer Patients. MOS 18.4 Months / Longer than Elahere 16.4 month MOS in the same Exact Setting - except 50% were refractory / 75% w Gps. $ABBV Paid $10B to buy Elahere $IMGN - and GPS PH2 trial results are better. ... https://www.fiercepharma.com/pharma/inside-abbvies-10b-immunogen-buyout-and-bidding-war-it-won $SLS is the Next $MRNA ---
2 · Reply
NotHopeJustFacts
NotHopeJustFacts Aug. 25 at 6:09 PM
$QTTB keep crying cause this molecule doesn't even match an already approved Rinvoq, why invest on an inferior product ? buy instead $ABBV if you care so much about Bold people, obviously is a stock for grown ups not a penny one
0 · Reply
DidYouReadThis
DidYouReadThis Aug. 25 at 5:43 PM
$ABBV YTD 12/31/26 predictions to be closest to?
0 · Reply